adagrasib
AXP000024.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Mirati Therapeutics
- Sponsor
- Bristol Myers Squibb
Names
Cross-references
- NCI Thesaurus
- C157493
- Wikidata
- Q105816120
- FDA UNII
- 8EOO6HQF8Y
Approvals
No regulatory approval recorded.
Clinical trials (39)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2026-10-15 | 2029-06-01 | 29 | Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
| NCT07723118 | A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent | Completed | Phase 1 | 2026-08-05 | 2026-09-08 | 10 | Healthy Participants |
| NCT07382726 | Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial | Recruiting | Phase 1 | 2026-05-15 | 2027-12-24 | 18 | Non-small Cell Lung Cancer |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | Recruiting | Phase 2 | 2026-05-06 | 2028-02-16 | 170 | Solid Tumors |
| NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial | Recruiting | Phase 2 | 2026-05-01 | 2028-10-08 | 535 | Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | Recruiting | Early phase 1 | 2026-04-22 | 2027-11-14 | 100 | Dynamic Tumor Resistance; Metastatic Colorectal Cancer |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Recruiting | Phase 3 | 2025-04-24 | 2029-09-07 | 630 | Carcinoma, Non-Small-Cell Lung |
| NCT06764771 | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | Recruiting | Phase 1 | 2025-03-25 | 2027-10-15 | 437 | Advanced Malignant Tumors |
| NCT06801418 | Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets | Completed | Phase 1 | 2025-02-04 | 2025-06-19 | 160 | Healthy Volunteers |
| NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Active not recruiting | Phase 3 | 2024-09-23 | 2026-05-19 | 338 | KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer |
| NCT06412198 | A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Recruiting | Phase 1/2 | 2024-08-28 | 2029-03-01 | 31 | KRAS G12C Mutations; Metastatic Colorectal Cancer |
| NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | Recruiting | Phase 2 | 2024-08-06 | 2027-02-25 | 30 | KRAS G12C; NSCLC; Non Small Cell Lung Cancer |
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Active not recruiting | Phase 2 | 2024-02-01 | 2026-10-30 | 200 | Advanced Cancer; Malignant Neoplasm of Lung; Metastatic Cancer |
| NCT06130254 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Terminated | Phase 1 | 2024-01-30 | 2024-06-14 | 1 | Advanced Solid Tumor; Non-small Cell Lung Cancers |
| NCT06039384 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Terminated | Phase 1 | 2023-12-28 | 2025-04-11 | 6 | Advanced Solid Tumors |
| NCT05722327 | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | Active not recruiting | Phase 1 | 2023-12-06 | 2027-09-30 | 24 | Colon Cancer; Colorectal Cancer |
| NCT06024174 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | Terminated | Phase 1/2 | 2023-11-09 | 2024-05-13 | 5 | Advanced Solid Tumors |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Recruiting | Phase 1 | 2023-10-18 | 2027-01 | 300 | Clear Cell Renal Cell Carcinoma (ccRCC); Colorectal Cancer (CRC); Non Clear Cell Renal Cell Carcinoma (nccRCC); Non Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Renal Cell Carcinoma (Kidney Cancer); Solid Tumors With HRAS Alterations |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | Terminated | Phase 1 | 2023-08-07 | 2024-12-27 | 6 | Advanced Cancer; Malignant Neoplastic Disease; Metastatic Cancer; NSCLC; Solid Tumor, Adult |
| NCT05924152 | A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib | Completed | Phase 1 | 2023-06-29 | 2023-08-09 | 16 | Healthy Adults |
| NCT05673187 | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status | Active not recruiting | Phase 2 | 2023-06-12 | 2025-07-28 | 68 | KRAS P.G12C; NSCLC Stage IV |
| NCT05868356 | A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib | Completed | Phase 1 | 2023-06-01 | 2023-07-25 | 18 | Healthy Adults |
| NCT05634525 | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | Withdrawn | Phase 1 | 2023-05-03 | 2025-07-21 | 0 | Metastatic Pancreatic Cancer |
| NCT05848843 | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | Phase 1 | 2023-04-25 | 2024-01-16 | 0 | Gastro-intestinal Cancer; Lung Cancer |
| NCT05472623 | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab | Withdrawn | Phase 2 | 2023-03-21 | 2025-06-01 | 0 | Resectable Non-Small Cell Lung Cancer |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Terminated | Phase 1 | 2022-12-02 | 2026-02-03 | 64 | Advanced Solid Tumor; Colo-rectal Cancer; Non Small Cell Lung Cancer; Solid Tumor |
| NCT05609578 | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Active not recruiting | Phase 2 | 2022-11-22 | 2026-09-30 | 90 | Advanced NSCLC; Metastatic Lung Cancer |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Completed | Phase 1/2 | 2022-08-01 | 2026-06-15 | 12 | Advanced Cancer; KRAS Activating Mutation; Malignant Neoplasm of Lung; Malignant Neoplastic Disease; Metastatic Cancer; Non Small Cell Lung Cancer |
| NCT05263986 | The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors | Unknown | Phase 1 | 2022-05-30 | 2023-10-31 | 22 | Advanced or Metastatic Solid Tumor |
| NCT05178888 | Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | Completed | Phase 1 | 2022-01-20 | 2023-06-15 | 11 | Advanced Solid Tumor |
| NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Terminated | Phase 1 | 2021-07-28 | 2022-11-02 | 7 | Advanced Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Lung; Malignant Neoplastic Disease; Metastatic Cancer |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Active not recruiting | Phase 3 | 2021-06-24 | 2026-01-16 | 461 | Advanced Colorectal Cancer; Metastatic Colorectal Cancer |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | Active not recruiting | Phase 3 | 2021-02-23 | 2023-12-30 | 453 | Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Recruiting | Phase 2/3 | 2020-12-02 | 2028-10-31 | 626 | Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer |
| NCT04418661 | Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | Terminated | Phase 1/2 | 2020-06-09 | 2024-04-04 | 65 | Metastatic Neoplasm |
| NCT04330664 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Completed | Phase 1 | 2020-04-07 | 2022-07-29 | 86 | Advanced Cancer; Malignant Neoplastic Disease; Metastatic Cancer |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | Active not recruiting | Phase 2 | 2019-10-17 | 2025-11-13 | 50 | CDK Gene Mutation; KRAS G12C Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; NTRK Family Gene Mutation; PI3K Gene Mutation; ROS1 Gene Mutation |
| NCT03785249 | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Active not recruiting | Phase 1/2 | 2019-01-15 | 2026-06-23 | 731 | Advanced Cancer; Malignant Neoplastic Disease; Metastatic Cancer |
| NCT05162443 | Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | Approved for marketing | Advanced Cancer; Malignant Neoplasm; Metastatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41907597 | Case Report: From metabolic normalization to incidental type A aortic dissection in immune checkpoint inhibitor-associated aortitis. | Frontiers in oncology | 2026 | name in abstract: adagrasib |
| PMID 42405535 | Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report. | The oncologist | 2026 | name in abstract: adagrasib |
| PMID 42528143 | ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC. | Thoracic cancer | 2026 | name in title: adagrasib |
| PMID 42745627 | Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations. | Future oncology (London, England) | 2026 | cited by trial NCT04685135 |
| PMID 42929675 | Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. | The New England journal of medicine | 2026 | cited by trial NCT06497556 |
| PMID 39752885 | Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT04793958 |
| PMID 40542959 | Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. | Advances in therapy | 2025 | name in title: adagrasib |
| PMID 40783289 | Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. | Lancet (London, England) | 2025 | cited by trial NCT04685135 |
| PMID 41029058 | Real-world adverse event analysis of Adagrasib: Insights from the FAERS database. | Medicine | 2025 | name in title: adagrasib |
| PMID 41355935 | Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation. | Case reports in oncological medicine | 2025 | name in abstract: adagrasib |
| PMID 38451823 | Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. | Anti-cancer drugs | 2024 | name in abstract: adagrasib |
| PMID 38550295 | Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report. | JTO clinical and research reports | 2024 | name in title: adagrasib |
| PMID 38579193 | Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review. | JCO precision oncology | 2024 | cited by trial NCT05472623 |
| PMID 38587856 | Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. | Cancer discovery | 2024 | name in title: adagrasib |
| PMID 38996797 | Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer. | European journal of cancer (Oxford, England : 1990) | 2024 | name in title: adagrasib |
| PMID 39534868 | Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report. | Case reports in oncology | 2024 | name in title: adagrasib |
| PMID 36546659 | Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. | The New England journal of medicine | 2023 | cited by trial NCT03785249 |
| PMID 37099736 | Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT03785249 |
| PMID 37327468 | Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT03785249 |
| PMID 35167329 | First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022 | cited by trial NCT03785249 |
| PMID 35404402 | Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | cited by trial NCT03785249 |
| PMID 35658005 | Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. | The New England journal of medicine | 2022 | cited by trial NCT03785249 |
| PMID 35666594 | Adagrasib Response Remains Strong in NSCLC. | Cancer discovery | 2022 | name in title: adagrasib |
| PMID 36353445 | Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants. | 3 Biotech | 2022 | name in abstract: adagrasib |
| PMID 34161704 | Acquired Resistance to KRASG12C Inhibition in Cancer. | The New England journal of medicine | 2021 | cited by trial NCT03785249 |
| PMID 31658955 | The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. | Cancer discovery | 2020 | name in title: MRTX849 |
| PMID 32479604 | Receptor discordance in breast cancer brain metastases: when knowledge is power. | Neuro-oncology | 2020 | cited by trial NCT03994796 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40011229 | Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database. | Expert opinion on drug safety | 2026 | name in title: adagrasib |
| PMID 40844328 | Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis. | American journal of clinical oncology | 2026 | name in title: adagrasib |
| PMID 40991960 | Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer. | Annual review of medicine | 2026 | name in abstract: adagrasib |
| PMID 41191614 | A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development. | Anti-cancer drugs | 2026 | name in abstract: adagrasib |
| PMID 41340466 | Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Molecular cancer therapeutics | 2026 | name in abstract: adagrasib |
| PMID 41453423 | Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer. | Acta biomaterialia | 2026 | name in abstract: adagrasib |
| PMID 41506251 | In-Source Fragmentation of Pyrrolidine-Containing KRAS Scaffolds Leads to Enhanced Structure Elucidation and Tandem Mass Spectral Quality. | Journal of the American Society for Mass Spectrometry | 2026 | name in abstract: adagrasib |
| PMID 41508946 | Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review). | Oncology reports | 2026 | name in abstract: adagrasib |
| PMID 41529383 | Advances on drug therapy for KRASG12C-mutant non-small-cell lung cancer. | Translational oncology | 2026 | name in abstract: adagrasib |
| PMID 41563236 | From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy. | International journal of surgery (London, England) | 2026 | name in abstract: adagrasib |
| PMID 41581311 | Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC. | Lung cancer (Amsterdam, Netherlands) | 2026 | name in abstract: adagrasib |
| PMID 41592443 | The Gaussian network model as a framework for allosteric analysis: dynamic distance, edge centrality, and entropy sensitivity in KRAS. | Physical biology | 2026 | name in abstract: adagrasib |
| PMID 41633936 | Design and Synthesis of KRASG12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically. | Journal of medicinal chemistry | 2026 | name in abstract: MRTX849 |
| PMID 41654096 | Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis. | Critical reviews in oncology/hematology | 2026 | name in abstract: adagrasib |
| PMID 41663526 | Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases. | Cancer gene therapy | 2026 | name in abstract: adagrasib |
| PMID 41670818 | Genomic alterations and their correlation with metabolic-related genes in lung cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2026 | name in abstract: adagrasib |
| PMID 41697749 | Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. | The Journal of clinical investigation | 2026 | name in abstract: adagrasib |
| PMID 41697929 | KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions. | Oncology research and treatment | 2026 | name in abstract: adagrasib |
| PMID 41715254 | The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation. | Biological research | 2026 | name in title: adagrasib |
| PMID 41784211 | A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science. | Cancer investigation | 2026 | name in abstract: adagrasib |
| PMID 41822354 | Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRASG12C inhibitors and degraders. | Frontiers in cell and developmental biology | 2026 | name in abstract: adagrasib |
| PMID 41830517 | MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS (G12C) cancer cells. | Molecular cancer therapeutics | 2026 | name in abstract: adagrasib |
| PMID 41888140 | Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations. | Nature communications | 2026 | name in abstract: MRTX849 |
| PMID 41898563 | MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. | International journal of molecular sciences | 2026 | name in abstract: adagrasib |
| PMID 41998662 | MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis. | Respiratory research | 2026 | name in abstract: adagrasib |
| PMID 42003513 | Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer. | Expert opinion on drug discovery | 2026 | name in abstract: adagrasib |
| PMID 42030031 | GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition. | Biological chemistry | 2026 | name in abstract: adagrasib |
| PMID 42031346 | From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC. | Critical reviews in oncology/hematology | 2026 | name in abstract: adagrasib |
| PMID 42041157 | MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells. | Molecular cancer therapeutics | 2026 | name in abstract: adagrasib |
| PMID 42055521 | KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status. | Cancer treatment and research communications | 2026 | name in abstract: adagrasib |
| PMID 42077604 | Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond. | Therapeutic advances in medical oncology | 2026 | name in abstract: adagrasib |
| PMID 42098425 | Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases. | Journal of neuro-oncology | 2026 | name in abstract: adagrasib |
| PMID 42114191 | Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells. | Bioorganic chemistry | 2026 | name in title: adagrasib |
| PMID 42114275 | KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians. | Cancer treatment reviews | 2026 | name in abstract: adagrasib |
| PMID 42122163 | Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation. | Cancers | 2026 | name in abstract: adagrasib |
| PMID 42170277 | Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors. | Translational lung cancer research | 2026 | name in abstract: adagrasib |
| PMID 42234744 | Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer. | Science advances | 2026 | name in abstract: adagrasib |
| PMID 42244998 | Development and in vivo evaluation of 18F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring. | Theranostics | 2026 | name in abstract: adagrasib |
| PMID 42254833 | Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis. | Neuro-oncology advances | 2026 | name in title: adagrasib |
| PMID 42258763 | KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones. | Cancer research | 2026 | name in abstract: adagrasib |
| PMID 42279426 | Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance. | Cancers | 2026 | name in abstract: adagrasib |
| PMID 42282123 | Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. | Journal of the National Cancer Center | 2026 | name in abstract: MRTX849 |
| PMID 42283833 | Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies. | Naunyn-Schmiedeberg's archives of pharmacology | 2026 | name in abstract: adagrasib |
| PMID 42290615 | Opioid toxicity from impaired oxycodone metabolism associated with adagrasib. | Clinical toxicology (Philadelphia, Pa.) | 2026 | name in title: adagrasib |
| PMID 42294187 | Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition. | ACS omega | 2026 | name in abstract: adagrasib |
| PMID 42325635 | Carborane Hydrophobic Tags Drive Selective Degradation of Endogenous KRASG12C via HSP70-Ubiquitin-Proteasome Pathway. | ACS bio & med chem Au | 2026 | name in abstract: MRTX849 |
| PMID 42336204 | Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2026 | name in abstract: adagrasib |
| PMID 42386216 | Targeting KRAS for cancer therapy. | British journal of pharmacology | 2026 | name in abstract: adagrasib |
| PMID 42398486 | In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer. | Journal of molecular graphics & modelling | 2026 | name in abstract: adagrasib |
| PMID 42446418 | Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors. | Journal of medicinal chemistry | 2026 | name in abstract: adagrasib |
| PMID 42448954 | KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. | Apoptosis : an international journal on programmed cell death | 2026 | name in abstract: adagrasib |
| PMID 42450070 | Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies. | International journal of molecular sciences | 2026 | name in abstract: adagrasib |
| PMID 42496289 | FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches. | Medicines (Basel, Switzerland) | 2026 | name in abstract: adagrasib |
| PMID 42511798 | KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. | International journal of molecular sciences | 2026 | name in abstract: adagrasib |
| PMID 42513436 | Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan. | Journal of clinical medicine | 2026 | name in title: adagrasib |
| PMID 42514855 | RAS Inhibitors: Changing the Paradigm from the Undruggable. | Pharmaceutics | 2026 | name in abstract: adagrasib |
| PMID 42551924 | [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: adagrasib |
| PMID 42551925 | [Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: adagrasib |
| PMID 42557306 | M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors. | Oncogene | 2026 | name in abstract: adagrasib |
| PMID 42571010 | The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. | Journal of hematology & oncology | 2026 | name in abstract: adagrasib |
| PMID 42593915 | Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor. | Journal of medicinal chemistry | 2026 | name in abstract: adagrasib |
| PMID 42611092 | KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions. | Journal of gastrointestinal cancer | 2026 | name in abstract: adagrasib |
| PMID 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: adagrasib |
| PMID 42624145 | Patient-reported outcomes with adagrasib in KRYSTAL-12. | Lancet (London, England) | 2026 | name in title: adagrasib |
| PMID 42688109 | Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies. | Frontiers in oncology | 2026 | name in abstract: adagrasib |
| PMID 42695382 | Clinicopathologically supported photodistributed hyperpigmentation with associated nail changes during adagrasib therapy. | Clinical and experimental dermatology | 2026 | name in title: adagrasib |
| PMID 42699034 | Theoretical study of KRAS G12C secondary mutations influencing inhibitor resistance. | Biophysics and physicobiology | 2026 | name in abstract: adagrasib |
| PMID 42707601 | KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies. | Frontiers in oncology | 2026 | name in abstract: adagrasib |
| PMID 42720810 | Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: adagrasib |
| PMID 42749446 | Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis. | Journal, genetic engineering & biotechnology | 2026 | name in abstract: adagrasib |
| PMID 42759542 | Targeting KRAS-Mutant Lung Cancers. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: adagrasib |
| PMID 42860233 | Blockade of mutant RAS oncogenic signaling: A 2026 update. | Pharmacological research | 2026 | name in abstract: adagrasib |
| PMID 42870846 | Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines. | Translational lung cancer research | 2026 | name in abstract: adagrasib |
| PMID 42890422 | Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management. | Cancer innovation | 2026 | name in abstract: adagrasib |
| PMID 42945155 | Divarasib Bests 1st-Generation KRASG12C Inhibitors. | Cancer discovery | 2026 | name in abstract: adagrasib |
| PMID 42967565 | Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC. | Cancer letters | 2026 | name in title: adagrasib |
| PMID 42975930 | Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression. | Proceedings of the National Academy of Sciences of the United States of America | 2026 | name in abstract: adagrasib |
| PMID 43001251 | From "undruggable" to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms. | Cancer pathogenesis and therapy | 2026 | name in abstract: adagrasib |
| PMID 43023285 | Mechanisms of Resistance to KRAS G12C Inhibitors and the Rationale for Targeting the PI3K/AKT/mTOR Pathway in Advanced NSCLC. | Mini reviews in medicinal chemistry | 2026 | name in abstract: adagrasib |
| PMID 37936461 | A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C). | Current medicinal chemistry | 2025 | name in abstract: adagrasib |
| PMID 38486394 | Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies. | Journal of biomolecular structure & dynamics | 2025 | name in abstract: adagrasib |
| PMID 39404173 | Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia. | Molecular cancer therapeutics | 2025 | name in abstract: adagrasib |
| PMID 39506389 | KRAS inhibitors in drug resistance and potential for combination therapy. | Tumori | 2025 | name in abstract: adagrasib |
| PMID 39522850 | KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies. | Critical reviews in oncology/hematology | 2025 | name in abstract: adagrasib |
| PMID 39587812 | Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions. | Clinical pharmacology and therapeutics | 2025 | name in title: adagrasib |
| PMID 39711431 | Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. | Molecular cancer therapeutics | 2025 | name in abstract: adagrasib |
| PMID 39725152 | WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer. | Cancer letters | 2025 | name in abstract: adagrasib |
| PMID 39732595 | KRAS inhibitors: resistance drivers and combinatorial strategies. | Trends in cancer | 2025 | name in abstract: adagrasib |
| PMID 39804166 | Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: adagrasib |
| PMID 39825361 | KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors. | Journal of translational medicine | 2025 | name in abstract: MRTX849 |
| PMID 39881149 | Comparative study of degree, neighborhood and reverse degree based indices for drugs used in lung cancer treatment through QSPR analysis. | Scientific reports | 2025 | name in abstract: adagrasib |
| PMID 39894719 | Adagrasib-induced photodistributed hyperpigmentation: Two case reports and pathogenetic hypothesis. | Therapie | 2025 | name in title: adagrasib |
| PMID 39914665 | Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. | Annals of oncology : official journal of the European Society for Medical Oncology | 2025 | name in abstract: adagrasib |
| PMID 39941797 | The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. | Cancers | 2025 | name in abstract: adagrasib |
| PMID 40009739 | The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results. | Deutsches Arzteblatt international | 2025 | name in abstract: adagrasib |
| PMID 40023579 | In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans. | Drug metabolism and disposition: the biological fate of chemicals | 2025 | name in abstract: adagrasib |
| PMID 40052089 | Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective. | RSC medicinal chemistry | 2025 | name in abstract: adagrasib |
| PMID 40082968 | ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. | Molecular cancer | 2025 | name in abstract: adagrasib |
| PMID 40093982 | Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions. | Therapeutic advances in medical oncology | 2025 | name in abstract: adagrasib |
| PMID 40109589 | Adagrasib plus cetuximab - a novel therapy in the KRAS G12C mutated colorectal cancer treatment. | Annals of medicine and surgery (2012) | 2025 | name in title: adagrasib |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| K01CA313805 | Targeting a novel covalent RAS dimer in RASQ61 mutants-driven cancers | UT SOUTHWESTERN MEDICAL CENTER | ZHOU, ZHIWEI | 2026–2026 | name in abstract: adagrasib |
| K22CA276357 | Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | ZHANG, HUA | 2024–2026 | name in abstract: MRTX849 |
| R01CA279264 | Mechanisms of adaptation and resistance to emerging therapies for lung cancer | SLOAN-KETTERING INST CAN RESEARCH | LITO, PIRO | 2023–2026 | name in abstract: adagrasib |
| R01CA281295 | KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition | UNIV OF NORTH CAROLINA CHAPEL HILL | CAMPBELL, SHARON L | 2023–2026 | name in abstract: adagrasib |
| R01CA285926 | Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer | MEDICAL UNIVERSITY OF SOUTH CAROLINA | OGRETMEN, BESIM | 2024–2026 | name in abstract: adagrasib |
| R01CA296154 | Highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancers | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | LIU, SHIHUI | 2025–2026 | name in abstract: adagrasib |
| R01CA296978 | Targeting molecular mechanisms of the adeno-to-squamous transition in non-small cell lung cancer treatment adaptation | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | YANAI, ITAI | 2025–2026 | name in abstract: adagrasib |
| R01CA311659 | Covalent Inhibitors of Ras Q61 Mutations in Cancer | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | HUANG, BENJAMIN | 2026–2026 | name in abstract: adagrasib |
| R21CA296712 | Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical release | COLD SPRING HARBOR LABORATORY | MOSES, JOHN EDWARD | 2025–2026 | name in abstract: adagrasib |
| U54CA224083 | Research Project 2 | WASHINGTON UNIVERSITY | LIM, KIAN-HUAT | 2023–2026 | name in abstract: adagrasib |
| R21CA297690 | Noncovalent interaction of mutant KRAS inhibitors | DUKE UNIVERSITY | CHI, JEN-TSAN ASHLEY | 2025–2025 | name in abstract: adagrasib |
| R21CA302807 | Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEEL, BENJAMIN G. | 2025–2025 | name in abstract: adagrasib |
| R44AI177220 | Mitigation of Radiation Induced Gastrointestinal Syndrome. | BCN BIOSCIENCES, LLC | NORRIS, ANDREW JOHN | 2023–2025 | name in abstract: adagrasib |
| ZIABC011892 | Targeting RAS in Pediatric Cancer | DIVISION OF BASIC SCIENCES - NCI | YOHE, MARIELLE | 2019–2025 | name in abstract: adagrasib |
| ZIASC006321 | Modulation of Therapeutic Response | DIVISION OF CLINICAL SCIENCES - NCI | MITCHELL, JAMES | 2024–2025 | name in abstract: adagrasib |
| F31CA261061 | Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC | WEILL MEDICAL COLL OF CORNELL UNIV | DIAZ, BIANCA | 2021–2024 | name in abstract: MRTX849 |
| R21CA282568 | Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach | H. LEE MOFFITT CANCER CTR & RES INST | HAURA, ERIC B. | 2023–2023 | name in abstract: adagrasib |
| ZIABC010440 | Protein Structure, Stability, and Amyloid Formation | DIVISION OF BASIC SCIENCES - NCI | NUSSINOV, RUTH | 2022–2023 | name in abstract: adagrasib |
Notes
KRAS G12C (OFF-state covalent). Mirati acquired by BMS Jan 2024. Approved (Krazati).
How to cite
adagrasib (AXP000024.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000024.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.